Cite
HARVARD Citation
von Minckwitz, G. et al. (2015). A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer. 121 (20), pp. 3639-3648. [Online].